Receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds

被引：17
|
作者：
Qu, Zechao [1 ]
Zhang, Bo [1 ]
Kong, Lingbo [1 ]
Gong, Yining [1 ]
Feng, Mingzhe [1 ]
Gao, Xiangcheng [1 ]
Wang, Dong [1 ]
Yan, Liang [1 ]
机构：
[1] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spinal Surg, Xian, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷
基金：
中国国家自然科学基金;
关键词：
osteoporosis; osteoclastogenesis; RANKL; signaling pathway; natural compounds; RANKL-INDUCED OSTEOCLASTOGENESIS; BONE; OSTEOPOROSIS; DIFFERENTIATION; INHIBITION; KINASE; AKT;
D O I：
10.3389/fphar.2022.1043975
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Osteoclast is a hematopoietic precursor cell derived from the mononuclear macrophage cell line, which is the only cell with bone resorption function. Its abnormal activation can cause serious osteolysis related diseases such as rheumatoid arthritis, Paget's disease and osteoporosis. In recent years, the adverse effects caused by anabolic anti-osteolytic drugs have increased the interest of researchers in the potential therapeutic and preventive effects of natural plant derivatives and natural compounds against osteolytic diseases caused by osteoclasts. Natural plant derivatives and natural compounds have become major research hotspots for the treatment of osteolysis-related diseases due to their good safety profile and ability to improve bone. This paper provides an overview of recent advances in the molecular mechanisms of RANKL and downstream signaling pathways in osteoclast differentiation, and briefly outlines potential natural compounds with antiosteoclast activity and molecular mechanisms.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] Curcumin Inhibits Osteoclastogenesis by Decreasing Receptor Activator of Nuclear Factor-κB Ligand (RANKL) in Bone Marrow Stromal Cells
    Oh, Sora
    Kyung, Tae-Wook
    Choi, Hye-Seon
    MOLECULES AND CELLS, 2008, 26 (05) : 486 - 489
  • [22] Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis
    Boopalan, Thiyagarajan
    Arumugam, Arunkumar
    Parada, Jacqueline
    Saltzstein, Edward
    Lakshmanaswamy, Rajkumar
    CANCER SCIENCE, 2015, 106 (01): : 25 - 33
  • [23] Molecular Basis of Requirement of Receptor Activator of Nuclear Factor κB Signaling for Interleukin 1-mediated Osteoclastogenesis
    Jules, Joel
    Zhang, Ping
    Ashley, Jason W.
    Wei, Shi
    Shi, Zhenqi
    Liu, Jianzhong
    Michalek, Suzanne M.
    Feng, Xu
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (19) : 15728 - 15738
  • [24] Predicting the Efficacy of Novel Synthetic Compounds in the Treatment of Osteosarcoma via Anti-Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Targets
    Zhang, Wenhua
    Xu, Siping
    Liu, Peng
    Li, Xusheng
    Yu, Xinyuan
    Kang, Bing
    MEDICINAL CHEMISTRY, 2024, 20 (07) : 733 - 740
  • [25] Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines
    Lin, Zhuoyuan
    Huang, Sheng
    LingHu, Xitao
    Wang, Yixiao
    Wang, Bin
    Zhong, Shaowen
    Xie, Shangyan
    Xu, Xiaohong
    Yu, Aorigele
    Nagai, Atsushi
    Kobayashi, Yuta
    Wa, Qingde
    Huang, Shuai
    BIOENGINEERED, 2022, 13 (02) : 2710 - 2719
  • [26] Receptor activator of nuclear factor kappa B (RANK) ligand mediated osteoclastogenesis and bone resorption in ankylosing spondylitis.
    Song, YW
    Im, CH
    Kang, EH
    Ki, JY
    Shin, DW
    Choi, HJ
    Chang, EJ
    Lee, EY
    Lee, YJ
    Lee, EB
    Kim, HH
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S640 - S640
  • [27] Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis
    Gong, Wei
    Dou, Huan
    Liu, Xianqin
    Sun, Lingyun
    Hou, Yayi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (10): : 886 - 893
  • [28] Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease
    Kiechl, Stefan
    Schett, Georg
    Schwaiger, Judith
    Seppi, Klaus
    Eder, Paula
    Egger, Georg
    Santer, Peter
    Mayr, Agnes
    Xu, Qingbo
    Willeit, Johann
    CIRCULATION, 2007, 116 (04) : 385 - 391
  • [29] How Is Receptor Activator of Nuclear Factor-κβ/Receptor Activator of Nuclear Factor-κβ Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?
    Chu, Quincy S. C.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : 1561 - 1564
  • [30] The Effect of Osteoprotectin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Gene Methylation on Aortic Valve Calcified
    Luo, Wei
    Song, Yanqiu
    Wang, Jing
    Yang, Xia
    Li, Zuocheng
    Cong, Hongliang
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
12345